IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences
11/01/2022 - 06:00 AM
SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in November 2022 and its plans to host an Investor R&D Day in December 2022 .
Jefferies London Healthcare Conference
Tuesday, November 15 th , 2022 at 5:00pm GMT // 12:00pm ET
Fireside chat with Yujiro Hata , Chief Executive Officer, IDEAYA Biosciences, hosted by Maury Raycroft Ph.D. Equity Research Analyst Stifel Healthcare Conference
Wednesday, November 16, 2022 at 8:00am ET
Fireside chat with Paul Stone , Chief Financial Officer, IDEAYA Biosciences, hosted by Ben Burnett , Ph.D. Vice President, Equity Analyst IDEAYA Biosciences Investor R&D Day
Monday, December 12, 2022 at 8:00am ET
A live audio webcast of conference events, as permitted by conference host, and of the Investor R&D Day webcast will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events . A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Quarterly Report on Form 10-Q filed on August 15, 2022 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact IDEAYA BiosciencesPaul Stone Senior Vice President and Chief Financial Officerinvestor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-plans-for-investor-rd-day-and-participation-in-upcoming-investor-conferences-301662966.html
SOURCE IDEAYA Biosciences, Inc.
IDYA Rankings
#381 Ranked by Stock Gains
IDYA Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Biotechnology, Pharmaceuticals: Major, Health Technology
Country
US
City
South San Francisco
About IDYA
ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.